4 2021 с обл

ONCOLOGY
BULLETIN
OF THE VOLGA REGION Vol. 12, no. 4. 2021
Финансирование
Исследование не имело спонсорской поддержки
Конфликт интересов
Авторы заявляют об отсутствии конфликта интересов
Литература
1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics,
2017 // CA Cancer J. Clin. — 2017. — 67. — P. 7-30.
[PubMed] [Google Scholar]
2. Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer
incidence and mortality worldwide: sources,
methods and major patterns in GLOBOCAN 2012 //
Int. J. Cancer. — 2015. — 136. — P. E359-E386.
[PubMed] [Google Scholar]
3. Arnold M., Karim-Kos H.E., Coebergh J.W., et al.
Recent trends in incidence of five common cancers
in 26 European countries since 1988: analysis of the
european cancer observatory // Eur. J. Cancer. — 2015.
— 51. — P. 1164-1187. [PubMed] [Google Scholar]
4. Состояние онкологической помощи населению
России в 2019 году / Под ред. А.Д. Каприна,
В.В. Старинского, А.О. Шахазадовой. — М.: МНИОИ
им. П.А. Герцена, 2020. — 239 с.
5. Benafif S., Kote-Jarai Z., Eeles R.A. PRACTICAL
Consortium. A review of prostate cancer genomewide
association studies (GWAS) // Cancer Epidemiol
Biomarkers Prev. — 2018. — 27. — P. 845-857.
[PMC free article] [PubMed] [Google Scholar]
6. Schumacher F.R., Al Olama A.A., Berndt S.I., et al.
Australian Prostate Cancer BioResource (APCB);
IMPACT Study; Canary PASS Investigators; Breast
and Prostate Cancer Cohort Consortium (BPC3);
PRACTICAL (Prostate Cancer Association Group to
Investigate Cancer-Associated Alterations in the
Genome) Consortium; Cancer of the Prostate in
Sweden (CAPS); Prostate Cancer Genome-wide
Association Study of Uncommon Susceptibility Loci
(PEGASUS); Genetic Associations and Mechanisms
in Oncology (GAME-ON)/Elucidating Loci Involved in
Prostate Cancer Susceptibility (ELLIPSE) Consortium.
Association analyses of more than 140,000 men
identify 63 new prostate cancer susceptibility loci //
Nat. Genet. — 2018. — 50. — P. 928-936. [PMC free
article] [PubMed] [Google Scholar]
7. Cancer Genome Atlas Research Network. The
molecular taxonomy of primary prostate cancer //
Cell. — 2015. — 163. — P. 1011-1025. [PMC free
article] [PubMed] [Google Scholar]
8. Kumar A., Coleman I., Morrissey C., et al. Substantial
interindividual and limited intraindividual genomic
diversity among tumors from men with metastatic
prostate cancer // Nat Med. — 2016. — 22. —
P. 369-378. [PMC free article] [PubMed] [Google Scholar]
9. Sultanbaev A., Menshikov K., Izmailov A., et al. Local
features of penetrant mutations incidence in patients
with prostate cancer in Republic of Bashkortostan //
European Urology Open Science. — Nov. 2021. —
Vol. 33, Suppl. 3. — P. S263. https://doi.org/10.1016/
S2666-1683(21)03123-2
10. Sultanbaev A., Izmailov A., Menshikov K., et al.
Screening for prostate cancer in a healthy population
with hereditary syndrome // European Urology Open
Science. — Nov. 2021. — Vol. 33, Suppl. 2. — P. S157.
https://doi.org/10.1016/S2666-1683(21)02733-6
11. Rong Na, S Lilly Zheng, Misop Han, et al. Germline
Mutations in ATM and BRCA1/2 Distinguish Risk
for Lethal and Indolent Prostate Cancer and are
Associated with Early Age at Death. // Eur. Urol. —
2017 May. — 71 (5). — P. 740-747. doi: 10.1016/j.
eururo.2016.11.033. Epub 2016 Dec 15.
12. Farmer H., Cabe N., Lord C.J. Targeting the DNA
repair defect in BRCA mutant cells as a therapeutic
strategy // Nature. — 2005. — 434. — 7035. — P. 917-921.
DOI: 10.1038/nature 03445.
13. Robson M., Seock-Ah Im, Senkus E. et al. Olaparib for
metastatic breast cancer in patients with a germline
BRCA mutation // N. Engl. J. Med. — 2017. — 377. —
P. 523-533. DOI: 10.1056/NEJMoa1706450.
14. Turk A.A., Wisinski K.B. PARP inhibitors in breast
cancer: Bringing synthetic lethality to the bedside //
Cancer. — 2018 Jun 15. — 124 (12). — P. 2498-2506.
doi: 10.1002/cncr.31307. Epub 2018 Apr 16.
PMID: 29660759; PMCID: PMC5990439.
15. Султанбаев А.В., Меньшиков К.В., Султанбаева Н.И.,
Мусин Ш.И. Организация скрининга рака предстательной
железы у носителей герминативных мутаций
в генах BRCA 1/2 // Онкоурология. Материалы
XV международного конгресса российского общества
онкоурологов. — 2020. — С. 52-53
Clinical case
67